Share

June 12, 2018; 90 (24) Editorial

Ameliorating the age at onset and disease progression in Huntington disease

Patrick J. Morrison, Martin B. Delatycki
First published May 9, 2018, DOI: https://doi.org/10.1212/WNL.0000000000005670
Full PDF
Citation
Permissions

Comment

Downloads
64

Share

Article Information

vol. 90 no. 24 1087-1088
DOI: 
https://doi.org/10.1212/WNL.0000000000005670
PubMed: 
29743206
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published May 9, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Information

    1. Patrick J. Morrison, CBE, MD, DSc and
    2. Martin B. Delatycki, MBBS, FRACP, PhD
  1. Patrick J. Morrison, CBE, MD, DSc and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. The Oncologist, Section editor, 2007-2017. uncompensated.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Martin B. Delatycki, MBBS, FRACP, PhD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associate Editor BMC Neurology 2008 to current Associate Editor Pediatric Genetics 2013 to current

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Victorian Clinical Genetics Services- Medical Director (Not for profit organisation) Murdoch Children's Research Institute- Director, Bruce Lefroy Centre (Not for profit organisation)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Reata- provide funding for a clinical trial of RTA408 for the treatment of Friedreich ataxia. I do not receive any personal remuneration from this.

    Research Support, Government Entities:

    1. Grants from National Health and Medical Research Council, Friedreich Ataxia Research Association and Friedreich Ataxia Research Alliance provides funding for my research but not for my salary

    Research Support, Academic Entities:

    1. Honorary Professor- University of Melbourne Honorary Professor- Monash University

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Genetic Medicine (P.J.M.), Belfast HSC Trust; Centre for Cancer Research and Cell Biology (P.J.M.), Queens University of Belfast, UK; Victorian Clinical Genetics Services (M.D.) and Bruce Lefroy Centre (M.D.), Murdoch Children's Research Institute, Parkville, Australia.
  1. Correspondence
    Prof. Morrison patrick.morrison{at}belfasttrust.hscni.net
View Full Text

Article usage

Article usage: May 2018 to August 2018

AbstractFullPdfSource
May 2018284025Highwire
Jun 20183045228Highwire
Jul 20189396Highwire
Aug 20186225Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

Topics Discussed

Alert Me